Catheter Precision, Inc.

During thethree months ended* September 30, 2025*, no director or officer, as defined in Rule16a-1(f) under the Securities Exchange Act of1934, as amended, of the Company adopted or terminated a "Rule10b5-1 trading arrangement" or "non-Rule10b5-1 trading arrangement," as each term is defined in Item408(a) of Regulation S-K.

On* July 11, 2025,two short term promissory notes of$150* thousand each were issued by the Company’s majority-owned subsidiary KardioNav to David Jenkins, the Company's Chairman of the Board and Chief Executive Officer, and Lifestim, Inc., a company controlled by Mr. Jenkins, in exchange for an aggregate loan of*$300* thousand. The promissory notes have a maturity date of* July 11, 2026,and interest rates of4.2%* per annum, with all principal and interest payable upon maturity. As of* September 30, 2025,**$300* thousand of principal was outstanding on the notes.

The notes, including all principal and interest, accelerate and become immediately due and payable upon the occurrence of certain customary events of default, including failure to pay amounts owed when due, material breach of the Company’s representations or warranties (unless waived by the holders or cured within10 days following notice), certain events involving the discontinuation of the Company’s business and/or certain types of proceedings involving insolvency, bankruptcy, receivership and the like.